Samrat Pharmachem Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Samrat Pharmachem Ltd. on BSE

Search Inside the pdf :

Samrat Pharmachem Ltd.

26 Jun 2025, 03:39PM

344.85

0.70%

Corp. Note

Samrat Pharmachem Ltd-$ - 530125 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySamrat Pharmachem Ltd- 2CIN NO.L24230GJ1992PLC017820 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY BBB- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Nishant Kankaria Designation: Company Secretary and Compliance Officer EmailId: contact@samratpharmachem.in Name of the Chief Financial Officer: Rajesh Mehta Designation: CFO EmailId: contact@samratpharmachem.in Date: 26/06/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Samrat Pharmachem Ltd.

23 Jun 2025

344.85

0.70%

Board Meeting

Samrat Pharmachem Ltd-$ - 530125 - Board Meeting Intimation for Un-Audited Financial Results For The Quarter …

BSE India

Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve the un-audited financial results for the quarter ended 30-06-2025

pdf

Samrat Pharmachem Ltd.

23 Jun 2025

344.85

0.70%

SAST

Samrat Pharmachem Ltd-$ - 530125 - Closure of Trading Window

BSE India

The Trading Window will remain closed from 01-07-2025 till 48 hours after declaration of UFR for the quarter ended 30-06-2025

pdf

Samrat Pharmachem Ltd.

03 Jun 2025

344.85

0.70%

Company Update

Samrat Pharmachem Ltd-$ - 530125 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Credit Rating

pdf

Samrat Pharmachem Ltd.

03 Jun 2025

344.85

0.70%

Company Update

Samrat Pharmachem Ltd-$ - 530125 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Copies of Newspaper Publication - Extract of Audited Financial Results FY 24-25 Q4

pdf

Samrat Pharmachem Ltd.

30 May 2025

344.85

0.70%

Result

Samrat Pharmachem Ltd-$ - 530125 - Audited Financial Results For The Year Ended March 31, 2025

BSE India

Audited Financial Results for the year ended March 31, 2025 Recommendation of Dividend @ 10% on paid up capital of the company

pdf

	Mar 2025	Dec 2024	Mar 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	71.10	63.67	82.98	11.7%	-14.3%
Operating Profit Qtr	0.13	4.17	1.36	-96.9%	-90.4%
Net Profit Qtr	-0.40	2.78	1.40	-114.4%	-128.6%
Earning Per Share Adjusted latest Qtr	-1.29	9.01	4.52	-114.3%	-128.5%

* Standalone data

Detailed Results

Samrat Pharmachem Ltd.

30 May 2025

344.85

0.70%

Board Meeting

Samrat Pharmachem Ltd-$ - 530125 - Board Meeting Outcome for Outcome Of Board Meeting Held Today

BSE India

Outcome of Board Meeting held today

pdf

Samrat Pharmachem Ltd.

30 May 2025

344.85

0.70%

Company Update

Samrat Pharmachem Ltd-$ - 530125 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Annual Secretarial Compliance Certificate for the year ended March 31, 2025

pdf

Samrat Pharmachem Ltd.

07 Apr 2025

344.85

0.70%

Company Update

Samrat Pharmachem Ltd-$ - 530125 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate u/r 74(5) for the quarter ended March 31, 2025

pdf

Samrat Pharmachem Ltd.

26 Mar 2025, 01:02PM

344.85

0.70%

Board Meeting

Samrat Pharmachem Ltd-$ - 530125 - Board Meeting Intimation for Notice Of Board Meeting For Approval …

BSE India

Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve the Audited Standalone Financial Results of the Company for the financial year ended March 31, 2025

pdf

Is Samrat Pharmachem Ltd. worth buying?

46 Votes:

Buy 67.39%

Sell 13.04%

Hold 19.57%